February 28, 2018

Solid Honors Rare Disease Day 2018

Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day, which takes place annually on February 28th. Rare Disease Day seeks to raise awareness of the current challenges faced by patients living with rare diseases. The campaign is spearheaded by the European Organisation for Rare Diseases (EURORDIS) and is observed globally.

As a company solely focused on Duchenne muscular dystrophy (DMD), Solid was honored to host several families with DMD, who shared their personal stories of living with this rare disease and educated our employees about DMD. It is their courage and drive that continue to inspire us in our important work every day. 

Rare Disease Day 2018

Related news


Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.


Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.


Today we are excited to announce the initiation of our first clinical trial for SGT-001.


Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.


Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 


New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development


We are getting ready to initiate a clinical study for our gene transfer candidate, SGT-001, later this year.


Solid Biosciences is pleased to announce additional research grant from our Australia-based partner Save Our Sons and an initial research grant from Ireland-based Join Our Boys.

  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.


More information about Solid?

Please subscribe to receive our latest news